Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd reported a weak Q2 FY26 with revenue from operations falling about 14.5% year-on-year to Rs 1,549.73 lakhs (from Rs 1,813.09 lakhs). Net profit dropped roughly 28.6% to Rs 163.85 lakhs (from Rs 229.59 lakhs), pushing EPS down to Rs 1.33 from Rs 1.96. For the half year, revenue declined about 3.4% to Rs 3,338.95 lakhs and net profit fell around 16% to Rs 336.91 lakhs. Cost of materials consumed surged sharply to Rs 1,066 lakhs from Rs 624 lakhs in the year-ago quarter, squeezing margins. Management blamed external disruptions: Nepal unrest blocking about Rs 10 million in export orders, tighter FDA scrutiny in Latin America, product approval delays in some markets, and the Iran-Israel conflict affecting container movement. The standalone operating cash flow remained negative at Rs -246.05 lakhs, though better than the prior year's Rs -508.83 lakhs. The auditor (R.B. Gohil & Co.) issued an unmodified limited review report.
Negative quarter on both top line and bottom line, mainly attributed by management to temporary, external export disruptions rather than weak demand. Investors should watch whether Q3 shows a rebound as deferred shipments are executed, but margin compression and weak cash generation remain near-term concerns.